Aktuellt
SENASTE
Redeye comments on Spago’s Q2 2022 report, following the company strengthening its cash position and anticipating several potential catalysts in the coming 12 months. We favorably view the company broadening its clinical pipeline with Tumorad in H2 2022E. Further, we suspect positive Spagopix top-line data and a potential partnership deal for that project constitute key catalysts in the near to medium term.
LÄS MER
